Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893929 | 0.91 | CHEK1 (1.00) | CHEK1ACHE | |
| SCHEMBL1895115 | 0.89 | CHEK1 (0.83) | CHEK1ACHE | |
| SCHEMBL1896626 | 0.87 | CHEK1 (0.79) | CHEK1ACHE | |
| SCHEMBL1559851 | 0.87 | CHEK1 (0.63) | CHEK1ACHE | |
| SCHEMBL12666764 | 0.85 | CHEK1 (0.77) | CHEK1ACHE | |
| SCHEMBL1888980 | 0.82 | CHEK1 (0.75) | CHEK1ACHE | |
| SCHEMBL13572761 | 0.82 | CHEK1 (0.75) | CHEK1ACHE | |
| SCHEMBL12666698 | 0.81 | CHEK1 (0.82) | CHEK1ACHE | |
| SCHEMBL12666697 | 0.81 | CHEK1 (0.82) | CHEK1ACHE | |
| SCHEMBL12666763 | 0.81 | CHEK1 (0.73) | CHEK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2300475-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300475-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHEK1 1/4885ACHE 4058/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHEK1 207/4885ACHE 1733/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHEK1 207/4885ACHE 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.